Locations:
Search
Benefits of neoadjuvant immunotherapy reflect emerging standard of care
Early results show strong clinical benefit rates
Phase 2 trials investigate sitagliptin and methimazole as adjuvant therapies
The shifting role of cell therapy and steroids in the relapsed/refractory setting
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Radiation therapy helped shrink hand nodules and improve functionality
Standard of care is linked to better outcomes, but disease recurrence and other risk factors often drive alternative approaches
Analysis of HNSCC patients shows HPV status to be predictive of higher abundance of oncobacteria within the tumor
Phase 1 study demonstrates immune response in three quarters of patients with triple-negative breast cancer
Multidisciplinary teams bring pathological and clinical expertise
Uterine transposition cleared the field for radiation therapy
Advertisement
Advertisement